Pitt and UPMC, through its Translational Sciences division, are once again collaborating to provide funding support for therapeutics projects that need further de-risking experiments to determine their clinical and commercial potential. We are featuring two projects that received funding from the first request for proposals from 2022.
Every other Tuesday, the Innovation Institute highlights a Pitt technology or a set of technologies from its portfolio of impactful innovations available for licensing or strategic partnerships. This week, we feature a technology that provides a novel approach to enhance gene therapy to treat diabetes.
Pitt innovators frequently share their stories with us of their moments of epiphany, when they realize that the blood, sweat and tears they have poured into their research has produced something that might have lasting value and can improve the world in some way. Sandra Katz studies peer-to-peer learning techniques at the University of Pittsburgh Learning Research & Development Center. While working with undergraduate seniors in the School of Health and Rehabilitation Science’s Emergency Medicine program to compare the effectiveness of different methods of de-briefing following an emergency medical scenario simulation, something interesting happened.
Pitt Duo Launches Innovative Shoe Insert to Help People With Foot Pain Beth and Jeff Gusenoff are a podiatrist and a plastic surgeon by trade, but entrepreneurs at heart. Over the past five years they have been developing a supportive pressure-reducing shoe insert crafted initially for their patients recovering from procedures that transfer fat to the bottom of the foot for various foot conditions. Now they have formally launched their company, PopSole™, hired a contract manufacturer in Western Pennsylvania and are pounding the pavement to find distribution partners.
Every other Tuesday, the Innovation Institute highlights a Pitt technology or a set of technologies from its portfolio of impactful innovations available for licensing or strategic partnerships. This week, we feature a technology that has the potential to treat infectious, inflammatory and post-traumatic disorders such as sepsis, necrotizing enterocolitis, autoimmune diseases, Crohn's disease, celiac disease, ulcerative colitis, cardiovascular disease and more. Researchers from the University of Pittsburgh and Johns Hopkins University have synthesized new carbon analogs of pyranose derivatives and approaches using these compounds may overcome some of the current challenges of cytokine inhibitors which often only target downstream cytokines and often play a less meaningful role in the inflammatory process.